January 1, 2014 | The Israeli company listed on NASDAQ NeuroDerm saw its share price doubled following the announcement of results from a Parkinson’s drug trial. According to the company, a mid-stage study showed that giving patients a higher dose of its Parkinson’s drug could allow them to avoid surgery in certain cases. NeuroDerm’s Parkinson’s medication is delivered through a waist-worn pump as compared to other methods delivered orally. As a result of the study’s conclusions, NeuroDerm’s share price doubled, reaching a record high of $14.12 and giving the company a market valuation of $231 million.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments